SK pharmteco

Adeno-associated virus (AAV) vectors are revolutionizing gene therapy, offering a highly precise and safe method for delivering life-changing therapies. However, ensuring the safety of these vectors in clinical applications is paramount. One significant challenge in biomanufacturing is the potential formation of replication-competent AAVs (rcAAVs), which pose safety risks. At SK pharmteco, we are at the forefront of addressing this challenge. Our rapid quantitative PCR (qPCR) assay, a cutting-edge cell-based technology, is designed to monitor the emergence of rcAAVs efficiently. Alongside this, we've developed innovative technologies to mitigate the risk of rcAAV formation, ensuring the highest safety standards. Our comprehensive approach supports gene therapy manufacturers by: 🔶 Sustaining High-Throughput Operations: Our technologies streamline biomanufacturing processes, enhancing productivity. 🔶Improving Quality Control: With precise monitoring, we ensure consistent and reliable quality in every batch. 🔶Enhancing Safety and Efficacy: By mitigating rcAAV risks, we help deliver safer and more effective gene therapies to patients. Read more about how we are transforming gene therapy manufacturing in this recent article with Genetic Engineering & Biotechnology News: https://lnkd.in/enYCpPdH

🌟 Meet Us at HPLC 2024! 🌟 Attending #HPLC2024 in Denver, CO July 20-25? Be sure to connect with Marc J Jacob, Ph.D. to discuss the latest advancements in liquid phase separations and related innovations. With decades of experience in manufacturing challenging chemistries, SK pharmteco has capabilities that support a wide range of processes and technologies. Whether you're interested in innovative separation techniques, cutting-edge technologies, or enhancing your analytical capabilities, we are here to help you find the perfect solutions. Can't wait to chat? Contact us to discover our capabilities: #ActivePharmaceuticalIngredients #AnalyticalServices #Chromatography

We are thrilled to announce that SK pharmteco's Audrey Greenberg will be speaking at Phacilitate Women in Advanced Therapies Global virtual event on July 10-11. Tune in tomorrow at 2 PM EDT to hear Audrey's valuable insights during the session, "Trailblazing Women in Biotech: Insights from Successful Female Founders & CEOs." WIAT Global is a digital event offering 24 hours of exclusive content tailored for industry leaders and innovators in the life sciences. This groundbreaking event brings together empowering women and their allies at the forefront of biotech, pharmaceuticals, and academia to drive progress in advanced therapies. Register for the event and explore the full agenda here: https://lnkd.in/eg9BW2eb #WIAT2024 #LifeSciences #WomenInLeadership #AdvancedTherapies #CGT #WomenInSTEM #Biotech #Pharmaceuticals #Innovation

Happy Independence Day from all of us at SK pharmteco! 🎆 Wishing everyone a safe and joyous Fourth of July filled with pride and gratitude. 

Oligonucleotides play a critical role in today's biotechnology and medical research, driving advancements in diagnostics, therapeutics, and genetic analysis. In a recent interview with Rizwan Chaudhrey, SK pharmteco's Marc J Jacob, Ph.D. shares our latest capabilities in oligonucleotides.   #biotech #biomanufacturing #advancedtherapies

At SK pharmteco, our viral vector manufacturing experts are dedicated to your projects, ensuring exceptional services and collaboration! For your cell or gene therapy needs, we provide comprehensive services from process development to commercial batches, for a seamless transition from innovation to market. Our commitment to quality and scalability ensures that we deliver impactful solutions globally, with manufacturing capabilities in Europe and the US.   Learn more and contact our experts: https://lnkd.in/eGS9emSW #ViralVector #CellandGeneTherapy #BioManufacturing

The rapid growth in cell and gene therapies has changed the landscape for CDMOs, and the need for all-inclusive, cost-effective, and low-risk alternatives to traditional manufacturing models is on the rise. Outsourcing is becoming a key strategy for many companies, enabling them to leverage specialized expertise, advanced technologies, and scalable solutions. This approach not only accelerates time-to-market but also enhances overall production quality and compliance. SK pharmteco stands at the forefront of this transformation with its state-of-the-art capabilities in cell and gene therapy manufacturing, offering comprehensive solutions that meet the highest standards of quality and innovation. Read more how CDMOs are elevating the CGT manufacturing game: https://lnkd.in/eskCwpq5 BioProcess International #CellandGeneTherapy #CDMO #biomanufacturing #CGT

Join us tomorrow as Audrey Greenberg provides the welcoming remarks at the Philadelphia Life Sciences Conference! This event will bring together industry leaders and experts from Philadelphia's life sciences sector as they discuss groundbreaking research, innovative technologies, funding strategies, regulatory landscapes, and more. This is a unique opportunity to delve into the topics crucial to the life sciences market. 📅 Date: Thursday, June 27, 2024 🕗 Time: 8:00 AM EDT 📍 Location: Live! Casino & Hotel, Philadelphia, PA Don't miss out—register now! Tickets are still available here: https://lnkd.in/e57D_dGv Bisnow #lifesciences #philadelphiabusiness

Revolutionize your #GeneTherapy manufacturing process with our cutting-edge Flexible Drug Product Vial Filler! SK pharmteco’s gloveless isolator technology ensures aseptic conditions and single-use capability, safeguarding against contamination and preserving product sterility. Discover the future of precision and flexibility in Gene Therapy production, contact us today to learn more! https://lnkd.in/egVykeW7 #AsepticTechnology #GeneTherapy #SterileProduct #BioTech

Organized jointly by SK pharmteco and ART-TG, the inaugural MOMENTUM in Cell and Gene Therapy convened on June 19, 2024, in Evry-Courcouronnes, France, bringing together world-renowned scientists, industry leaders, suppliers, CDMOs, students, and other stakeholders. This event marked a significant milestone in advancing the future of cell and gene therapies. The event opened with a keynote address by Dr. Bruce Levine, renowned for his pioneering work in genetically engineered T-cells, captivated attendees with insights into translating innovative therapies into transformative patient outcomes. Dr. Michael Hudecek, from Wurtzburg University opened the afternoon session with a keynote address that delved into the latest advancements in engineered T-cell therapies, highlighting achievements within European networks. Closing the symposium, Audrey Greenberg examined the thriving biotech ecosystem of Philadelphia as a model for accelerating the global delivery of cell and gene therapies. She emphasized the critical part that universities play in driving innovation, as well as the replicability of successful clusters and strategies to enhance collaboration and drive funding to support the growth in the cell and gene therapy space. #CellTherapy #GeneTherapy #MOMENTUM2024 #BiotechInnovation